SubtypeDrug: a software package for prioritization of candidate cancer subtype-specific drugs

Abstract

Summary Cancer can be classified into various subtypes by its molecular, histological or clinical characteristics. Discovering cancer-subtype-specific drugs is a crucial step in personalized medicine. SubtypeDrug is a system biology R-based software package that enables the prioritization of subtype-specific drugs based on cancer expression data from samples of many subtypes. This provides a novel approach to identify the subtype-specific drug by considering biological functions regulated by drugs at the subpathway level. The operation modes include extraction of subpathways from biological pathways, identification of dysregulated subpathways induced by each drug, inference of sample-specific subpathway activity profiles, evaluation of drug-disease reverse association at the subpathways level, identification of cancer-subtype-specific drugs through subtype sample set enrichment analysis, and visualization of the results. Its capabilities enable SubtypeDrug to find subtype-specific drugs, which will fill the gaps in the recent tools which only identify the drugs for a particular cancer type. SubtypeDrug may help to facilitate the development of tailored treatment for patients with cancer. Availability and implementation The package is implemented in R and available under GPL-2 license from the CRAN website (https://CRAN.R-project.org/package=SubtypeDrug). Supplementary information Supplementary data are available at Bioinformatics online.

Multiple Laplacian Regularized RBF Neural Network for Assessing Dry Weight of Patients With End-Stage Renal Disease

“…Deep learning ( Dao et al, 2021 ; Lv et al, 2021a , b ) also made a great contribution to the clinic, including skin cancer ( Esteva et al, 2017 ), breast cancer ( Liu J. et al, 2021 ), and brain diseases ( Liu G. et al, 2018 ; Liu et al, 2019 ; Bi et al, 2020 ; Hu et al, 2020 , 2021a , b ). In biological field, machine learning has been widely used to solve biological problems, including O -GlcNAcylation site prediction ( Jia et al, 2018 ), microbiology analysis ( Qu et al, 2019 ), microRNAs and cancer association prediction ( Zeng et al, 2018 ), lncRNAs ( Cheng et al, 2016 ; Deng et al, 2021 ), CircRNAs ( Fang et al, 2019 ; Zhao et al, 2019 ), DNA methylation site ( Wei et al, 2018b ; Zou et al, 2019 ; Dai et al, 2020 ), osteoporosis diagnoses ( Su et al, 2020b ), function prediction of proteins ( Wei et al, 2018a ; Wang H. et al, 2019 ; Deng et al, 2020b ; Ding et al, 2020a ; Su et al, 2020a ), nucleotide binding sites ( Ding et al, 2021b ), drug complex network analysis ( Ding et al, 2019 , 2020b , a ; Deng et al, 2020a ; Han et al, 2021 ; Liu H. et al, 2021 ), protein remote homology ( Liu B. et al, 2018 ), electron transport proteins ( Ru et al, 2019 ), and cell-specific replication.…”

Identification of Biomarkers for Cervical Cancer Radiotherapy Resistance Based on RNA Sequencing Data

“…Although radiotherapy for cervical cancer has been widely used, the emergence of radioresistance has deeply affected its treatment effect ( Kaidar-Person et al, 2012 ; Han et al, 2021 ). Consequently, overcoming the radiotherapy resistance of cervical cancer and finding related accurate biomarkers are essential and urgently needed.…”

Identification of Somatic Mutation-Driven Immune Cells by Integrating Genomic and Transcriptome Data

“…Recently, a number of calculated methods have been developed to identify dysregulated genes and pathways in cancer using molecular omics data (genome or transcriptome) ( Cheng et al, 2019 ; Han et al, 2020 ; Sheng et al, 2021 ). Moreover, some methods were proposed to prioritize cancer candidate drugs and prognostic markers ( Han et al, 2018 , 2021 ; Di et al, 2019 ). However, the methods for identifying immune cells driven by specific somatic mutations are mainly based on biological experiments, and as far as we have known, no calculated tools could systematically identify mutation-specific immune cells.…”